AdΔ24 and the p53‐expressing variant AdΔ24‐p53 achieve potent anti‐tumor activity in glioma when combined with radiotherapy
- 26 October 2007
- journal article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 9 (12) , 1046-1056
Abstract
Background The conditionally replicating adenovirus (CRAd) AdΔ24‐p53 replicates selectively in Rb mutant cells, and encodes the p53 suppressor protein. It has shown improved oncolytic potency compared to the parental control AdΔ24. As exogenous p53 has been shown to enhance radiosensitivity, the combination of AdΔ24‐p53 and AdΔ24 with radiotherapy was assessed in vitro and in vivo against the therapy resistant gliomas. Methods In glioma cells, multicellular spheroids and animal xenografts the efficacy of combination therapy was assessed. P53 phosphorylation, induction of apoptosis and viral replication were determined following single or combination therapies. Results In vitro, AdΔ24‐p53 was more effective against glioma cells than the control AdΔ24. Addition of irradiation equally increased the efficacy of both AdΔ24‐p53 and AdΔ24 resulting in improved oncolysis compared to single agent treatment. Radiotherapy did not significantly change the replication kinetics of AdΔ24‐p53 or AdΔ24. No detectable increase in p53 phosphorylation was observed but combination of radiotherapy and AdΔ24‐p53 caused an increase in the percentage of apoptotic cells. In vivo, combination therapy with either AdΔ24 or AdΔ24‐p53 significantly increased the number of mice demonstrating tumor regression (100%) as well as long‐term survival (50%). No differences between viruses were noted. Conclusions Exogenous p53 expression does not appear to increase the synergistic interaction of CRAds combined with radiotherapy. These results however do indicate that radiotherapy provides the time frame in which AdΔ24 and AdΔ24‐p53 can eradicate established tumors that would otherwise escape treatment, and establishes the need to combine these modalities to form an effective anti‐cancer treatment. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- Cyclophosphamide Allows for In vivo Dose Reduction of a Potent Oncolytic VirusCancer Research, 2005
- Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificityCancer Gene Therapy, 2005
- Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus AdΔ24-p53 against Human Malignant GliomaCancer Research, 2004
- Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) proteinCancer Gene Therapy, 2003
- Late Expression of p53 from a Replicating Adenovirus Improves Tumor Cell Killing and Is More Tumor Cell Specific than Expression of the Adenoviral Death ProteinHuman Gene Therapy, 2002
- Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinomaCancer Gene Therapy, 2002
- E1B-Deleted Adenovirus ( dl 1520) Gene Therapy for Patients with Primary and Secondary Liver TumorsHuman Gene Therapy, 2001
- Quiescence in S-phase and G 1 arrest induced by irradiation and/or hyperthermia in six human tumour cell lines of different p53 statusInternational Journal of Radiation Biology, 2000
- Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and RbOncogene, 1999
- Combined radiation and p53 gene therapy of malignant glioma cellsCancer Gene Therapy, 1999